menu
    • menu
    [{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nevanimibe","moa":"Sterol O-acyltransferase (SOAT)","graph1":"Oncology","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Millendo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nevanimibe","moa":"Sterol O-acyltransferase (SOAT)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Millendo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Millendo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nevanimibe","moa":"Sterol O-acyltransferase (SOAT)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Millendo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Millendo Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Nevanimibe

    Menu

    Nevanimibe

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

                            Details : ATR-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cushing Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2017

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

                            Details : ATR-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Adrenal Hyperplasia, Congenital.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2016

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Millendo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

                            Details : ATR-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Adrenocortical Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2013

                            Lead Product(s) : Nevanimibe

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth